Valeritas gets US nod to use V-Go device to deliver Novo Nordisk's insulin
This article was originally published in Clinica
The US FDA has granted 510(k) clearance for the use of the V-Go disposable insulin delivery device, developed by Valeritas, with Novo Nordisk's NovoLog, a fast-acting form of insulin. V-Go permits continuous subcutaneous delivery of insulin in preset basal rates, along with on-demand bolus dosing for adult patients. Patients with type 2 diabetes apply a new V-Go to the skin daily for 24 hours. In December, the FDA cleared use of the V-Go with Eli Lilly's Humalog fast-acting insulin. NovoLog and Humalog are the two most widely prescribed fast-acting insulins in the US, Bridgewater, New Jersey-based Valeritas says.
You may also be interested in...
Dr Noam Emanuel is the founder and chief technology officer of Ness Ziona, Israel-based drug delivery firm PolyPid. The 15-strong firm, established in 2008, has developed an encapsulation technology which allows the precise targeting of drug release.
Mesoblast has received the all-clear from the US FDA to start a Phase III clinical trial for bone marrow regeneration in patients with blood cancers. The study will be conducted together with Mesoblast's strategic alliance partner, Cephalon, which will fund the trial.
Mesoblast has received the green light from the US FDA to begin a Phase II trial of its proprietary adult mesenchymal precursor cell (MPC) product for the treatment of degenerative disc disease, a major cause of chronic low back pain.